No differentiation for Roche's degrader
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Olema takes its antagonist/degrader concept into phase 3
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
